Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Capital Expenditures (2016 - 2025)

Abeona Therapeutics (ABEO) has 14 years of Capital Expenditures data on record, last reported at $5.5 million in Q3 2025.

  • For Q3 2025, Capital Expenditures rose 529.76% year-over-year to $5.5 million; the TTM value through Sep 2025 reached $9.1 million, up 4383.74%, while the annual FY2024 figure was $2.4 million, 638.97% up from the prior year.
  • Capital Expenditures reached $5.5 million in Q3 2025 per ABEO's latest filing, up from -$37000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $5.5 million in Q3 2025 and bottomed at -$1.3 million in Q3 2024.
  • Average Capital Expenditures over 5 years is $771111.1, with a median of $160500.0 recorded in 2022.
  • Peak YoY movement for Capital Expenditures: skyrocketed 9742.42% in 2021, then crashed 2986.36% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at $3.2 million in 2021, then plummeted by 99.23% to $25000.0 in 2022, then soared by 48.0% to $37000.0 in 2023, then skyrocketed by 6062.16% to $2.3 million in 2024, then surged by 139.39% to $5.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $5.5 million in Q3 2025, -$37000.0 in Q2 2025, and $1.4 million in Q1 2025.